Agile Therapeutics Inc. (AGRX) Sees Large Volume Increase
Agile Therapeutics Inc. (NASDAQ:AGRX) shares saw unusually-high trading volume on Thursday . Approximately 185,150 shares traded hands during trading, an increase of 173% from the previous session’s volume of 67,845 shares.The stock last traded at $7.19 and had previously closed at $6.99.
AGRX has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 price objective on shares of Agile Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research raised shares of Agile Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Tuesday, May 10th. FBR & Co reissued a “buy” rating and set a $17.00 price objective on shares of Agile Therapeutics in a report on Tuesday, May 10th. Finally, Noble Financial reissued a “buy” rating and set a $15.00 price objective on shares of Agile Therapeutics in a report on Friday, July 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $15.00.
The firm’s market cap is $199.25 million. The company’s 50-day moving average price is $7.11 and its 200 day moving average price is $6.63.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.29). Equities analysts predict that Agile Therapeutics Inc. will post ($1.24) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Agile Therapeutics stock. Marshall Wace LLP boosted its position in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent filing with the SEC.
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.